Carotid Artery Disease How the Data Will Influence Management The Symptomatic vs. the Asymptomatic Patient

Similar documents
How to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention

Carotid Artery Stenosis

Carotid Endarterectomy vs. Carotid artery Stenting (Surgeon Perspective)

Carotid Artery Stenting Versus

Update : Carotid Stenting and Current Trial Data

Carotid Artery Stent: Is it ready for prime time?

Carotid stenosis management: CAS or CEA? Yaoguo Yang, Chen Zhong Beijing Anzhen Hospital,China

Peter A. Soukas, M.D., FACC, FSVM, FSCAI, RPVI

Carotid Artery Stenting

FRANK J. VEITH MAC TH MUNICH VASCULAR CONF

The Great Swedish Debate. Håkan Pärsson Department Vascular Surgery Helsingborgs Lasarett, University Lund

Disclosures. State of the Art Management of Carotid Stenosis. NIH funding for clinical trials Consultant for Scientia Vascular and Medtronic

Which Patients Are Good Candidates for Carotid Artery Stenting or Carotid Endarterectomy

CardioLucca2014. Fare luce sulla scelta ottimale del trattamento nella rivascolarizzazione delle stenosi carotidee. Fabrizio Tomai

Contemporary Management of Carotid Disease What We Know So Far

CLINICAL TIMELINE EVA-3S CREST ICSS SPACE SAPPHIRE

Carotid Artery Revascularization: Current Strategies. Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014

The argument against revascularization for asymptomatic carotid stenosis

The most important recommendations from the 2017 ESVS/ESC guideline on the management of carotid artery disease

Joshua A. Beckman, MD. Brigham and Women s Hospital

CAROTID STENTING A 2009 UPDATE. Hoang Duong, MD Director of Interventional Neuroradiology Memorial Regional Hospital

New Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008

Asymptomatic Carotid Stenosis To Do or Not To Do

My Latest Take on RCT Data: When is CEA or CAS the Best Option? The Interventional Position

The Effectiveness of Medical Therapy for Severe Carotid Stenosis in Reducing Large-Vessel Embolic Stroke: Open Question or Question Answered?

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

UPMC HAMOT CAROTID ARTERY DISEASE WHERE DO WE GO FROM HERE?

MORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS. 73 year old NS right-handed male applicant for $1 Million Life Insurance

Approach to Intervention in Carotid Artery Disease. Kenneth Rosenfield, M.D. Section Head Vascular Medicine and Intervention MGH Boston, MA

TCAR: TransCarotid Artery Revascularization Angela A. Kokkosis, MD, RPVI, FACS

I have the following potential conflicts of interest to report. honorarium: 1. St Jude Medical 2. Biotronik 3. Boston Scientific

MEET Θ symptomatic patients. K. Mathias Department of Radiology Teaching Hospital of Dortmund - Germany

Octogenarians Must Be Treated With CAS

MORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS. 73 year old NS right-handed male applicant for $1 Million life insurance

Carotid artery percutaneous treatment: back to the future Alberto Cremonesi MD, FESC

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Treatment Considerations for Carotid Artery Stenosis. Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery

Update on Carotid Disease

LARGE ARTERY DISEASE pathophysiology of ischemic insults. ISCHEMIC STROKE & TIA main etiologies

Surgical Treatment of Carotid Disease

DESCRIPTION: Percent of asymptomatic patients undergoing CEA who are discharged to home no later than post-operative day #2

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

ISCHEMIC STROKE & TIA main etiologies

Index. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.

CEA or CAS for asymptomatic carotid stenosis which patients benefit most?

Carotid Artery Stenting Today: A Few Updating Remarks

Carotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO

Alma Mater Studiorum Università di Bologna

ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH

Will guidelines and clinical practice for asymptomatic stenosis change in the near future?

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

BULgarian Carotid Artery Stenting versus Surgery Study (BULCASSS): Randomized single center trial

ASYMPTOMATIC CAROTID STENOSIS WE CAN (AND SHOULD) CHOOSE PATIENTS FOR ASYMPTOMATIC CAROTID STENOSIS TREATMENT BASED ON SURVIVAL PREDICTIONS

CAROTID DEBATE High-Grade Asymptomatic Disease Should Be Repaired Selectively; Medical Management is NOT Enough

ESC Heart & Brain Workshop

DWMRI Lesions, Cranial Nerve Injury & Neuropsychometric Testing: Is It Time To Incorporate These Outcomes In Carotid Trials As Primary Endpoints?

Slide 1. Slide 2 Conflict of Interest Disclosure. Slide 3 Stroke Facts. The Treatment of Intracranial Stenosis. Disclosure

Issam D. Moussa, MD. Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, FL

Review of clinical carotid stent procedural & long-term outcomes in. symptomatic asymptomatic. patients

Update on the only remaining Carotid Multicenter Randomised International Trial in the World:ACST-2

Endovascular vs Surgical Carotid Revascularisation

Current Status and Perspectives of ACST-2, CREST-2, ECST-2 and ACTRIS. Richard Bulbulia Co-Principal Investigator ACST-2 University of Oxford

DESPITE CURRENT LEVEL 1 EVIDENCE THE OUTLOOK FOR AN UPSURGE IN CAROTID STENTING (CAS) IS BRIGHT FRANK J. VEITH LINC LEIPZIG JANUARY 27, 2015

Why I do not believe the

New concepts for filter protection during CAS: double filtration. Alberto Cremonesi MD, FESC

Carotid Artery Stenting

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Carotid Stenting: (An) American Perspective. Kenneth Rosenfield, M.D. Section Head Vascular Medicine and Intervention MGH Boston, MA

Fast-track CEA: a 3-year experience

Clinical experience amongst surgeons in the Asymptomatic Carotid Surgery Trial-1 (ACST-1)

Asymptomatic carotid disease in patients with CAD in light of emerging stent and balloon technologies: is conservative treatment still appropriate?

Carlo Setacci Chief Department of Surgery Vascular and Endovascular Unit University of Siena

Carotid. The. Issue. Now approved by the FDA, carotid stenting moves into the spotlight in endovascular care.

CAROTID ANGIOPLASTY AND STENTING UNDER PROTECTION IS BECOMING THE GOLD STANDARD TREATMENT IN HIGH AND LOW RISK PATIENTS

Extracranial Carotid Artery/Stenting

Lecture Outline: 1/5/14

Impact of the Aortic Arch on Stent Performance

Carotid Disease and CABG: What is the best Treatment

TIA SINGOLO E IN CRESCENDO: due diversi scenari della rivascolarizzazione urgente carotidea

Carotid Artery Stenting (CAS) Pathophysiology. Technical Considerations. Plaque characteristics: relevant concepts. CAS and CEA

Pre-and Post Procedure Non-Invasive Evaluation of the Patient with Carotid Disease

CAROTID ARTERY ANGIOPLASTY

Carotid Endarterectomy versus Carotid Angioplasty Cui Bono *

Carotid Artery Stenting

Approach to the Patient with Carotid Artery Disease

Advances in Prevention and Treatment of Stroke: What Every Primary Care Physician Needs to Know. Case 1 4/5/11. What treatment should you initiate?

Post-op Carotid Complications A Nursing Perspective of What to Watch Out for

PREDICTORS OF PERI-PROCEDURAL OUTCOMES OF CAS A REAL WORLD EXPERIENCE

The argument against revascularization for asymptomatic carotid stenosis

Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre

Most Important Clinical Trials of the Past Decade in Vascular Intervention

Renal Artery Stenting

Hidden coronary disease in carotid patients

Extracranial Carotid Artery/Stenting

Plaque protrusion during carotid artery stenting: risk factors determined by MR plaque imaging

Stroke prevention in asymptomatic carotid stenosis. ΛΙΛΛΗΣ ΛΕΩΝΙΔΑΣ Καρδιολόγος Επιστημονικός Συνεργάτης Α Καρδιολογικής Κλινικής ΑΠΘ ΠΓΝΘ ΑΧΕΠΑ

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Non-Selective Carotid Artery Ultrasound Screening in Patients Undergoing Coronary Artery Bypass Grafting: Is It Necessary?

CAS as first line of treatment in the future

Open heart surgery or carotid endarterectomy. Which procedure should be done first?

Transcription:

Carotid Artery Disease How the 2014-2015 Data Will Influence Management The Symptomatic vs. the Asymptomatic Patient Christopher J. White, MD, MSCAI, FACC, FAHA, FESC Professor and Chair of Medicine Ochsner Clinical School and Ochsner Medical Center New Orleans, LA

Relationships with industry: Research: None Stock Ownership: None Speakers Bureau: None Consultant: None DISCLOSURE Relevant to Carotid Artery Stenting

Stroke Prevention Carotid plaque most often causes symptoms due to EMBOLIZATION, rather than thrombosis. Extracranial carotid OCCLUSION is the source of ischemic stroke in fewer than 20%. Symptomatic patients have a much higher stroke rate than asymptomatic patients. Asymptomatic patients outnumber symptomatic patients by 4:1.

FACT(s) We do NOT need more trials to establish equipoise for CAS vs. CEA CAS is one of the most studied procedures of all time. 7 systems approved as safe and effective by the FDA, all with pivotal and post-approval trials, that account for more than 10,000 published cases. 3 poorly executed European trials (SPACE, EVA-3s, & ICSS) tell us trainees cannot do CAS as well as experienced surgeons can do CEA. SAPPHIRE, a small RCT in high surgical risk patients, showed that CAS is the procedure of choice in those pts. CREST was a very large, well conducted trial in average risk patients with no difference between CEA and CAS.

Stroke Prevention

BARRIERS to CAS Low volumes. No reimbursement. Nallamothu, BK et al JAMA. 2011;306(12):1338-1343

Do I Have to Explain Why Experience Matters? Hopkins LN, et al. J. Stroke and Cerebrovascular Dis. 2010;19:153-162 Lin PH, et al. Am J Surg. 2005;190:855-863

Unadjusted Patient Outcomes by Annual Operator Volume P < 0.001 P < 0.001 2.5 1.9 1.6 1.4 Nallamothu, BK et al JAMA. 2011;306(12):1338-1343

CREST 2500 PATIENTS RANDOMIZED Level I Evidence for Equipoise CAS = CEA for Average Surgical Risk

CREST 4-Yr Stroke Events No statistical difference for stroke out to 4 years between CAS and CEA. Brott TG, et. al N Engl J Med. 2010;363:11-23.

EQUIPOISE FOR CAS & CEA WE DON T NEED MORE TRIALS.WE NEED TO USE THE DATA WE HAVE TO ALLOW PHYSICIANS AND PATIENTS TO MAKE REASONABLE CHOICES, BASED UPON THE EVIDENCE. Patients with CAD. Younger age. Experienced operator. Experienced team. High CAS risk. Older age. Experienced operator. Experienced team. CAS CEA

FACT(s) One size does not fit all There IS overall equipoise for CEA and CAS but. Patient selection for CEA/CAS should be individualized. Operator and Institutional volume matter for outcome quality in both CEA and CAS. Symptomatic patients have more to gain than Asx. Younger patients have more to gain, over the long-term, from revascularization, than do the very elderly.

High Surgical Risk Stent CEA %Difference [95% C.I.] Sapphire: Level I evidence supporting equipoise for CAS and CEA. 12.0% (20/167) 19.2% (32/167) 7.2%[ 14.9%, 0.6%] Non-inferiority limit Stent Better CEA Better 2002 2012

CAS Preferred in High Surgical Risk Patients Some patients present difficult challenges for CEA, and may be offered CAS as an alternative. Some patients who are at increased risk for CEA will strongly prefer CAS. Assumes operator and institutional experience and a track record for safety and quality.

Percent Choosing Treatment Options 67-year-old man with a carotid bruit and 70%-80% RICA. nonsmoker hypertension hyperlipidemia LICA 20% stenosis. Klein, A, et al. New England Journal of Medicine 358.20 (2008): 1617-1621.

Asymptomatic Carotid Stenosis ACAS 1 and ACST 2 in the 1990 s: CEA vs. MED 5 yr relative risk reduction for ipsilateral stroke 50%. 1 yr absolute risk reduction of 0.5% to 1.0%. NNT 100-200 to prevent one stroke per year. CEA did not reduce combined stroke and death. CEA did not benefit women. CEA did not benefit men 75 years. CMS 2004-2006 Asx CEA = 88%, Asx CAS = 87%. 1. Barnett HJ, et. al. N Engl J Med 1998; 339:1415 25. 2. Halliday A, et al. Lancet 2010;376: 1074 84.

Asymptomatic Carotid Stenosis Risk of progression to occlusion is low. ACST 1 : 1,469 MED Group: 94 progressed to occlusion. 12 with symptoms. 1 with stroke. Yang et al 2.: 3,681 MED for 20 yrs. 254/316 (80%) Occlusions before 2002. Only 1 stroke with occlusion. Occlusion by Year (Yang et al. 2 ) Intensity of MED Rx 1. Halliday A, et al. Lancet 2010;376: 1074 84. 2. Yang, et al. JAMA Neurol. doi:10.1001/jamaneurol.2015.1843

Asymptomatic Carotid Stenosis Percent Stenosis Plaque Burden P = 0.80 P = 0.006 Yang, et al. JAMA Neurol. doi:10.1001/jamaneurol.2015.1843

Consensus CAS vs. CEA Asymptomatic Selection of asymptomatic patients for revascularization should be based on comorbid conditions and patient life expectancy (Class I, Level of Evidence: C). Highly selected patients may benefit from CEA if the perioperative stroke/death rate is <3% (Class IIa, Level of Evidence: A). CAS might be considered in highly selected patients if the perioperative stroke/death rate is <3% (Class IIb, Level of Evidence: B). The usefulness of CAS is not well established for patients at high risk for CEA (Class IIb, Level of Evidence: C). Symptomatic Patients with a TIA or stroke 6 months and ipsilateral severe stenosis (70% to 99%), CEA is recommended if the perioperative stroke/death rate is estimated to be <6% (Class I, Level of Evidence: A). CAS is indicated as an alternative to CEA if the anticipated perioperative stroke/death rate is <6% (Class IIa, Level of Evidence: B). When revascularization is indicated, it is reasonable to perform it within 2 weeks rather than delay (Class IIa, Level of Evidence: B). It is reasonable to consider patient age in choosing between CEA and CAS (Class IIa, Level of Evidence: B). Chaturvedi, S. et al. J Am Coll Cardiol. 2015; 65(11):1134 43.

FACT(s) Patients hard to operate on safely. Class III/IV angina. Class III/IV heart failure. Intrathoracic or intracerebral lesions. Prior neck surgery or RT. Patients hard to place stents safely. Type III Aortic Arch. Tortuous and calcified lesions. Unable to use EPD. Difficult vascular access.

High Surgical Risk No Yes Stroke Prevention Strategy Revascularization includes aggressive risk factor modification. or vs. vs. Uncertain? Uncertain CAS or MED CAS/CEA or MED No CAS CAS or CEA Yes Symptoms Sapphire CREST or

Thank You